Cerus Endovascular Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cerus Endovascular Ltd. - overview
Established
2011
Location
Oxford, -, UK
Primary Industry
Medical Devices & Equipment
About
Cerus Endovascular Inc. is a medical technology company focused on developing innovative solutions for minimally invasive endovascular procedures, aiming to improve patient outcomes in vascular surgeries. Founded in 2011 in Oxford, UK, Cerus Endovascular Inc. specializes in advanced endovascular therapy technologies.
In September 2022, Stryker Corporation agreed to acquire Cerus from its investors for USD 530 mn, completing the deal in May 2023 for USD 300 mn in cash, with future milestone payments up to USD 225 mn. The acquisition is part of Stryker's strategy to enhance its offerings in global markets. Cerus Endovascular Inc. provides pioneering medical devices aimed at enhancing minimally invasive endovascular procedures.
Their products include cutting-edge technologies designed for vascular interventions, catering specifically to healthcare professionals involved in treating vascular diseases and improving surgical outcomes. In 2023, Cerus Endovascular Inc. reported a revenue of USD 1,733,591. 50, with an EBITDA of USD 136,067,768.
80, reflecting the company's financial performance in the medical technology sector. Following its acquisition by Stryker Corporation, Cerus plans to leverage additional resources to accelerate the development of new endovascular products aimed at enhancing procedural efficacy. The company is also targeting expansion into markets in Europe and Asia-Pacific by 2024, utilizing recent funding to support these initiatives and bolster its product development pipeline.
Current Investors
SPARK Ventures, North West Business Finance, Mid Atlantic Bio Angels
Primary Industry
Medical Devices & Equipment
Sub Industries
Biotechnology, Medical Devices & Equipment, Biomaterials
Website
www.cerusendo.com
Verticals
HealthTech, Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Cerus Endovascular Ltd. - timeline of key events
Cerus Endovascular Ltd. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (1,766,459) | (3,942,237) | (5,636,992) | - | - | - | - | - | - |
| Operating Income (USD) | (1,773,941) | (3,969,720) | (5,680,748) | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (1,472,383) | (3,547,433) | (5,280,669) | - | - | - | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - |
Cerus Endovascular Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.